Trial Profile
A retrospective study assessing safety and efficacy of Dupilumab in patients with Eczema Herpeticum history.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Mar 2018
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- 23 Mar 2018 New trial record
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology